Not for redistribution without written consent of Morgan Stanley

Morgan Stanley | RESEARCH

UPDATE

November 3, 2026 03:15 AM GMT

Lumentum Holdings Inc | North America

LITE FQ1 / Acquisition Announcement - Read-Throughs into our Coverage

MRVL/LITE underscores the strategic value of scarce optical assets, reinforced by LITE's strong results and NPO/CPO momentum. We see strategic rationale, although surprised about timing ahead of key ramps. Scarcity value of assets a positive for COHR; see more as a headwind for CIEN longer term.

What was announced. Following last week's Bloomberg report, Marvell (covered by Joe Moore) and Lumentum announced a definitive agreement on Monday, November 2, under which MRVL will acquire LITE in an all-stock transaction (see our first-take note). LITE shareholders will receive 4.5 MRVL shares for each LITE share, implying a transaction enterprise value of approximately $115bn, or $1,132 per LITE share, and a 23.9% premium to unaffected October 28 price. MRVL and LITE shareholders will own approximately 67% and 33% of the combined company, respectively, on a fully diluted basis. Management expects the transaction to close in 1H CY28, with Matt Murphy remaining CEO and Chairman and three LITE directors, including CEO Michael Hurlston, joining MRVL's board. MRVL expects more than $1bn in annual run-rate cost synergies, primarily from COGS, and non-GAAP EPS accretion in the first year following closing. Management expects a 1H CY28 close, with potential regulatory extensions through August 2028. We do not see another buyer given the size of the transaction.

Our initial perspective remains largely unchanged, with the transaction highlighting the strategic importance of optical technology and manufacturing capacity. We see rationale in combining MRVL's optical DSPs, switching and connectivity solutions with LITE's laser technology, InP manufacturing assets and growing NPO/CPO and OCS opportunities. LITE's recent earnings momentum and > $5bn in NPO/CPO commitments further highlight the value of its assets, though the sold out conditions through FY28 leave little unknown. Given deal approval not expected until the 1H'CY28, focus in the interim to be around ramping OCS / CPO capacity to be able to hit >$5bn targets.

Read-through to our coverage – supply tightness likely to persist, with mixed implications for COHR. For CIEN, LITE is a key component supplier for pump lasers and narrow line width lasers. While some of that bottleneck should clear over the next year and a half during the approval process, MRVL is a major competitor to CIEN on the ZR pluggables side, making relying on a competitor for supply of key products awkward (similar dynamics existed for NOK / Infinera when Acacia was acquired by Cisco). For COHR, from a strategic perspective, the transaction further validates the importance and scarcity value of COHR's optical technology and

MORGAN STANLEY & CO. LLC

Meta A Marshall
Equity Analyst
Meta.Marshall@morganstanley.com +1 212 761-0430

Joseph Moore
Equity Analyst
Joseph.Moore@morganstanley.com +1 212 761-7516

Antonio Jaramillo
Research Associate
Antonio.Jaramillo@morganstanley.com +1 212 761-4438

Lumentum Holdings Inc (LITE.O, LITE US)

Telecom & Networking Equipment | United States of America

Stock Rating	**Equal-weight**
Industry View	**In-Line**
Price target	**$1,000.00**
Shr price, close (Nov 2, 2026)	$684.40
Mkt cap, curr (mm)	$69,603
52-Week Range	$1,143.00-184.20

Fiscal Year Ending	06/26	06/27e	06/28e	06/29e
ModelWare EPS ($)	6.55	19.44	33.28	45.95
EPS ($)**	8.68	25.19	38.82	51.28
Div yld (%)	-	-	-	-

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare framework
** = Based on consensus methodology
e = Morgan Stanley Research estimates

QUARTERLY EPS ($)

Quarter	2026	2027e Prior	2027e Current	2028e Prior	2028e Current
Q1	1.10	-	4.57a	7.49	8.42
Q2	1.67	4.96	6.04	8.62	9.69
Q3	2.37	5.55	6.83	8.98	10.07
Q4	3.23	6.33	7.71	9.53	10.60

e = Morgan Stanley Research estimates, a = Actual Company reported data

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

manufacturing assets. This is offset by competitive dynamics on transceivers. We also don't have a sense of how much MRVL would like to get the transceiver assembly business, but definitely consolidates more of the BOM of a transceiver with one vendor, a headwind for the space.

F1Q27 margin upside, a second major NPO/CPO win and strong F2Q guidance. LITE reported revenue of $1.263bn (+25.5% Q/Q), ~0.6% above consensus but below the ~$1.28bn buyside bogey. Non-GAAP GM of 53.2% was ~170bps above consensus and in line with buyside expectations, while operating margin of 42.3% was ~250bps above consensus and ahead of the ~41% buyside bogey. EPS of $4.57 was ~9% above consensus and ahead of buyside expectations of $4.40-$4.45. Key incremental disclosure was a second major NPO/CPO win backed by >$5bn in purchase commitments, providing further validation of customer demand for next-generation optical scale-up architectures (though we would note the company had already alluded to this in media appearances during the quarter). Management also highlighted pump lasers and OCS as the leading growth contributors, with significantly improved OCS demand visibility supporting the potential for a multi-billion-dollar annual revenue stream. For F2Q, revenue guidance of $1.60bn was ~7% above consensus and at the high end of the $1.55bn-$1.60bn bogeys, implying ~ $350mm of sequential growth. EPS guidance of $6.05 was ~19% above consensus, with non-GAAP operating margin guidance of 45-46% pointing to another ~270-370bps of sequential expansion as the business continues to scale.


Risk Reward – Lumentum Holdings Inc (LITE.O)

AI More Embedded Into Base Case, Greater CPO Adoption is Bull Case

PRICE TARGET $1,000.00


25x CY28 P/E of ~$40. ~25x is a premium to historical trading range given AI growth outlook

Consensus Price Target Distribution



Source: Refinitiv, Morgan Stanley Research

RISK REWARD CHART AND OPTIONS IMPLIED PROBABILITIES (12M)




Key: Historical Stock Performance ● Current Stock Price ◆ Price Target

Source: Refinitiv, Morgan Stanley Research, Morgan Stanley Institutional Equities Division. The probabilities of our Bull, Base, and Bear case scenarios playing out were estimated with implied volatility data from the options market as of 2 Nov 2026. All figures are approximate risk-neutral probabilities of the stock reaching beyond the scenario price in either three-months' or one-years' time. View explanation of Options Probabilities methodology here

EQUAL-WEIGHT THESIS

- Datacom positioning attractive, particularly with ramping customer sets, but questions remain on margin contribution and impacts to earnings power
- Key questions remain on magnitude and timeline of OCS ramp and length of EML shortage.
- Upside to multiple likely limited by optical componentry being some of names most at risk from tariffs given intricate manufacturing that should be slower to move out of Asia, with LITE concentrated in Thailand

Consensus Rating Distribution



Source: Refinitiv, Morgan Stanley Research

Risk Reward Themes

Secular Growth: *Positive*

View descriptions of Risk Rewards Themes here

BULL CASE $1,500.00

~30x CY28 Bull Case Earnings Power (~$50)

CPO penetration greater than expected. LITE able to achieve ~$50 in CY28 EPS in our bull case as multiple business lines ramp -- including CPO seeing far greater adoption in scale-up / out than expected in early days. Exert meaningful pricing pressure, which maintains through CY28. Multiple remains at premium given growth outlook, particularly on scale-up.

BASE CASE $1,000.00

~25x CY28 P/E (~$40)

Broad-based AI growth. Ramps to EMLs, Telco (DCI), transceiver, OCS and CPO business concurrently. Margin benefit from EML constraints and higher blend of EML / OCS/ CPO. Our multiple is a premium to historical trading range given AI capex spend.

BEAR CASE $450.00

15x CY28 Bear Case Earnings Power (~$30)

Product lines have trouble ramping. OCS and CPO do not ramp to expectations on expected timeline. EMLs demand/supply reach equilibrium sooner than expected, pressuring margins. More signs that EMLs will lose share to CW (Silicon Photonics). Multiple trades closer to traditional ranges.

Risk Reward – Lumentum Holdings Inc (LITE.O)


KEY EARNINGS INPUTS

Drivers	Jun 2026	Jun 2027e	Jun 2028e	Jun 2029e
Total Revenue ($, mm)	3,014	6,224	10,027	13,318
Gross Margin (%)	46.0	52.2	53.6	53.8
Operating Margin (%)	29.8	41.2	43.8	45.2
EPS Growth Y/Y (%)	322.1	143.2	64.2	32.9

INVESTMENT DRIVERS

- Opportunities like 3D sensing still in early days
- ROADMs in early days of deployment in China
- Position as a consolidator as leverage levers more reasonable

GLOBAL REVENUE EXPOSURE



Source: Morgan Stanley Research Estimate
View explanation of regional hierarchies here

MS ALPHA MODELS

5/5 BEST	24 Month Horizon	5/5 MOST	3 Month Horizon

Source: Refinitiv, FactSet, Morgan Stanley Research; 1 is the highest favored Quintile and 5 is the least favored Quintile

RISKS TO PT/RATING

RISKS TO UPSIDE

- Datacom ramps and revenue mix more attractive vs. expectations
- OCS ramps quickly, bringing additional revenue / profitability source
- AI demand remains strong, causing EML business to outperform and drive profitability
- CPO / NPO ramp faster than expected

RISKS TO DOWNSIDE

- EML pricing falls given oversupply on reduced AI demand
- CW takes share from EML
- Cloud Light hurts ability to improve margins
- Pushout in CPO timing

OWNERSHIP POSITIONING

Inst. Owners, % Active	53.9%
HF Sector Long/Short Ratio	2.2x
HF Sector Net Exposure	30.6%

Refinitiv; MSPB Content. Includes certain hedge fund exposures held with MSPB. Information may be inconsistent with or may not reflect broader market trends. Long/Short Ratio = Long Exposure / Short exposure. Sector % of Total Net Exposure = (For a particular sector: Long Exposure - Short Exposure) / (Across all sectors: Long Exposure – Short Exposure).

MS ESTIMATES VS. CONSENSUS

FY Jun 2027e

Sales / Revenue ($, mm)	5,614	6,224 / 6,273	7,221
EBITDA ($, mm)	2,339	2,790 / 2,787	3,534
Net income ($, mm)	1,812	2,186 / 2,170	2,685
EPS ($)	17.92	21.10 / 21.54	25.27

Mean Morgan Stanley Estimates

Source: Refinitiv, Morgan Stanley Research

Valuation Methodology and Risks

Marvell Technology Group Ltd (MRVL.O)

~46X CY27e Base Case MW EPS $6.54, a premium to high growth AI semis

Risks to Upside

- AI opportunities (Inphi optical businesses) realize earlier than expected
- Cloud custom silicon projects are larger than expected
- The storage market recovers

Risks to Downside

- AI opportunities are smaller than expected
- The strength we estimate for Storage and Networking surprise to the downside
- Enterprise DC and Networking continue to weigh on results



Risk Reward Reference links

1. View explanation of Options Probabilities methodology - Options_Probabilities_Exhibit_Link.pdf

2. View descriptions of Risk Rewards Themes - RR_Themes_Exhibit_Link.pdf

3. View explanation of regional hierarchies - GEG_Exhibit_Link.pdf

4. View explanation of Theme/Exposure methodology - ESG_Sustainable_Solutions_External_Link.pdf

5. View explanation of HERS methodology - ESG_HERS_External_Link.pdf

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared by Morgan Stanley & Co. LLC, and/or Morgan Stanley C.T.V.M. S.A., and/or Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V.. As used in this disclosure section, "Morgan Stanley" includes Morgan Stanley & Co. LLC, Morgan Stanley C.T.V.M. S.A., Morgan Stanley Mexico, Casa de Bolsa, S.A. de C.V. and their affiliates as necessary.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/eqr/disclosures/webapp/generalresearch, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Meta A Marshall; Joseph Moore.

.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies. A Portuguese version of the policy can be found at www.morganstanley.com.br

Important Regulatory Disclosures on Subject Companies

The analyst or strategist (or a household member) identified below owns the following securities (or related derivatives): Antonio Jaramillo - Advanced Micro Devices(common or preferred stock), Arista Networks(common or preferred stock), Astera Labs Inc(common or preferred stock), Broadcom Inc.(common or preferred stock), Qualcomm Inc.(common or preferred stock), Wolfspeed, INC(common or preferred stock); Meta A Marshall - Advanced Micro Devices(common or preferred stock), Broadcom Inc.(common or preferred stock), Corning Inc(common or preferred stock), NVIDIA Corp.(common or preferred stock).

As of September 30, 2026, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Advanced Micro Devices, Aeva Technologies Inc, Allegro Microsystems Inc, Ambarella Inc, Amkor Technology Inc, Analog Devices Inc., Arista Networks, Arm Holdings plc, Astera Labs Inc, Axon Enterprise Inc, Broadcom Inc., Cadence Design Systems Inc, Cerebras Systems, Ciena Corporation, Cisco Systems Inc, Coherent Corp, Corning Inc, F5 Inc, Infleqtion, Inc., Intel Corporation, IonQ Inc, Keysight Technologies Inc, **Lumentum Holdings Inc**, Marvell Technology Group Ltd, Microchip Technology Inc., Micron Technology Inc., Motorola Solutions Inc, NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., PDF Solutions Inc, Qualcomm Inc., SanDisk Corporation., Semtech Corp., Silicon Laboratories Inc., SiTime Corporation, Skyworks Solutions Inc, Synopsys Inc., Texas Instruments, Wolfspeed, INC, Xanadu Quantum Technologies Limited, Zebra Technologies Corporation.

Within the last 12 months, Morgan Stanley managed or co-managed a public offering (or 144A offering) of securities of Advanced Micro Devices, Aeva Technologies Inc, Analog Devices Inc., Axon Enterprise Inc, Broadcom Inc., Cerebras Systems, GlobalFoundries Inc, Intel Corporation, NVIDIA Corp., ON Semiconductor Corp., PDF Solutions Inc, Quantinuum, SiTime Corporation.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from Advanced Micro Devices, Aeva Technologies Inc, Allegro Microsystems Inc, Amkor Technology Inc, Analog Devices Inc., Axon Enterprise Inc, Broadcom Inc., Cerebras Systems, GlobalFoundries Inc, Intel Corporation, IonQ Inc, Micron Technology Inc., Navitas Semiconductor Corp, NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., PDF Solutions Inc, Quantinuum, SanDisk Corporation., Semtech Corp., SiTime Corporation, Texas Instruments.

In the next 3 months, Morgan Stanley expects to receive or intends to seek compensation for investment banking services from Advanced Micro Devices, Aeva Technologies Inc, Allegro Microsystems Inc, Ambarella Inc, Amkor Technology Inc, Analog Devices Inc., Arista Networks, Arm Holdings plc, Astera Labs Inc, Axon Enterprise Inc, Broadcom Inc., Cadence Design Systems Inc, Cerebras Systems, Ciena Corporation, Cisco Systems Inc, Coherent Corp, Corning Inc, F5 Inc, GlobalFoundries Inc, Intel Corporation, IonQ Inc, Keysight Technologies Inc, **Lumentum Holdings Inc**, Marvell Technology Group Ltd, Microchip Technology Inc., Micron Technology Inc., Motorola Solutions Inc, Navitas Semiconductor Corp, NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., PDF Solutions Inc, Qualcomm Inc., Quantinuum, SanDisk Corporation., Semtech Corp., Silicon Laboratories Inc., SiTime Corporation, Skyworks Solutions Inc, Synopsys Inc., Texas Instruments, Wolfspeed, INC, Xanadu Quantum Technologies Limited, Zebra Technologies Corporation.

Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Advanced Micro Devices, Allegro Microsystems Inc, Ambarella Inc, Analog Devices Inc., Axon Enterprise Inc, Broadcom Inc., Cadence Design Systems Inc, Cerebras Systems, Ciena Corporation, Cisco Systems Inc, Coherent Corp, Corning Inc, GlobalFoundries Inc, Intel Corporation, **Lumentum Holdings Inc**, Microchip Technology Inc., Micron Technology Inc., Motorola Solutions Inc, NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., Qualcomm Inc., SanDisk Corporation., Semtech Corp., Silicon Laboratories Inc., SiTime Corporation, Texas Instruments, Zebra Technologies Corporation.

Within the last 12 months, Morgan Stanley has provided or is providing investment banking services to, or has an investment banking client relationship with, the following company: Advanced Micro Devices, Aeva Technologies Inc, Allegro Microsystems Inc, Ambarella Inc, Amkor Technology Inc, Analog Devices Inc., Arista Networks, Arm Holdings plc, Astera Labs Inc, Axon Enterprise Inc, Broadcom Inc., Cadence Design Systems Inc, Cerebras Systems, Ciena Corporation, Cisco Systems Inc, Coherent Corp, Corning Inc, F5 Inc, GlobalFoundries Inc, Intel Corporation, IonQ Inc, Keysight Technologies Inc, **Lumentum Holdings Inc**, Marvell Technology Group Ltd, Microchip Technology Inc., Micron Technology Inc., Motorola Solutions Inc, Navitas Semiconductor Corp, NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., PDF Solutions Inc, Qualcomm Inc., Quantinuum, SanDisk Corporation., Semtech Corp., Silicon Laboratories Inc., SiTime Corporation, Skyworks Solutions Inc, Synopsys Inc., Texas Instruments, Wolfspeed, INC, Xanadu Quantum Technologies Limited, Zebra Technologies Corporation.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Advanced Micro Devices, Allegro Microsystems Inc, Ambarella Inc, Analog Devices Inc., Axon Enterprise Inc, Broadcom Inc., Cadence Design Systems Inc, Cerebras Systems, Ciena Corporation, Cisco Systems Inc, Coherent Corp, Corning Inc, GlobalFoundries Inc, Intel Corporation, IonQ Inc, **Lumentum Holdings Inc**, Microchip Technology Inc., Micron Technology Inc., Motorola Solutions Inc, NVIDIA Corp., NXP Semiconductor NV, ON Semiconductor Corp., Qualcomm Inc., SanDisk Corporation., Semtech Corp., Silicon Laboratories Inc., SiTime Corporation, Texas Instruments, Wolfspeed, INC, Zebra Technologies Corporation.

Morgan Stanley & Co. LLC makes a market in the securities of Aeva Technologies Inc, Axon Enterprise Inc, Keysight Technologies Inc, Motorola Solutions Inc, PDF Solutions Inc, Zebra Technologies Corporation.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues. Equity Research analysts' or strategists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Morgan Stanley trades or may trade as principal in the debt securities (or in related derivatives) that are the subject of the debt research report.
Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of October 31, 2026)
The Stock Ratings described below apply to Morgan Stanley's Fundamental Equity Research and do not apply to Debt Research produced by the Firm.
For disclosure purposes only (in accordance with FINRA requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

	Coverage Universe		Investment Banking Clients (IBC)			Other Material Investment Services Clients (MISC)	
Stock Rating Category	Count	% of Total	Count	% of Total IBC	% of Rating Category	Count	% of Total Other MISC
Overweight/Buy	1575	43%	460	49%	29%	742	44%
Equal-weight/Hold	1537	42%	393	42%	26%	720	43%
Not-Rated/Hold	2	0%	1	0%	50%	1	0%
Underweight/Sell	570	15%	92	10%	16%	218	13%
Total	3,684		946			1681	

Data include common stock and ADRs currently assigned ratings. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months. Due to rounding off of decimals, the percentages provided in the "% of total" column may not add up to exactly 100 percent.

Analyst Stock Ratings


Overweight (O). The stock's total return is expected to exceed the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
Equal-weight (E). The stock's total return is expected to be in line with the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
Not-Rated (NR). Currently the analyst does not have adequate conviction about the stock's total return relative to the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
Underweight (U). The stock's total return is expected to be below the average total return of the analyst's industry (or industry team's) coverage universe, on a risk-adjusted basis, over the next 12-18 months.
Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.

Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.
In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below.
Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant broad market benchmark, as indicated below.
Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Stock Price, Price Target and Rating History (See Rating Definitions)

Lumentum Holdings Inc (LITE.O) - As of 11/03/26 GMT in USD
Industry : Telecom & Networking Equipment



Stock Rating History: 11/1/21 : E/I; 4/12/22 : E/C; 12/13/23 : E/I


Price Target History: 5/12/21 : 81; 11/4/21 : 91; 2/3/22 : 97; 5/2/22 : 94; 8/16/22 : 98; 10/11/22 : 84; 11/8/22 : 75; 12/13/22 : 66; 4/5/23 : 60; 5/9/23 : 55; 10/27/23 : 45; 12/13/23 : 52; 2/8/24 : 50; 8/14/24 : 54; 10/17/24 : 61; 11/14/24 : 76; 12/17/24 : 83; 1/31/25 : 81; 4/8/25 : 40; 5/6/25 : 70; 6/3/25 : 76; 7/8/25 : 85; 8/4/25 : 92; 8/12/25 : 100; 10/10/25 : 145; 11/5/25 : 190; 12/17/25 : 304; 1/30/26 : 350; 2/3/26 : 420; 2/23/26 : 520; 3/18/26 : 595; 4/19/26 : 710; 5/6/26 : 900; 8/12/26 : 1000

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target No Price Target Assigned (NA)
Stock Price (Not Covered by Current Analyst) Stock Price (Covered by Current Analyst)
Stock and Industry Ratings (abbreviations below) appear as ◆ Stock Rating/Industry View
Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)
Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Marvell Technology Group Ltd (MRVL.O) - As of 11/03/26 GMT in USD
Industry : Semiconductors



Stock Rating History: 11/1/21 : E/I; 12/7/23 : E/A

Price Target History: 10/7/21 : 63; 12/2/21 : 86; 3/3/22 : 80; 5/26/22 : 68; 6/9/22 : 62; 8/25/22 : 60; 12/1/22 : 41; 3/2/23 : 45; 5/25/23 : 55; 6/15/23 : 68; 8/25/23 : 65; 11/30/23 : 63; 3/4/24 : 84; 3/7/24 : 71; 5/30/24 : 77; 8/29/24 : 82; 12/3/24 : 102; 12/19/24 : 120; 1/27/25 : 113; 3/6/25 : 90; 5/27/25 : 70; 5/29/25 : 73; 7/29/25 : 80; 8/29/25 : 76; 11/30/25 : 86; 12/2/25 : 112; 3/1/26 : 95; 3/6/26 : 103; 5/25/26 : 172; 5/27/26 : 195; 8/23/26 : 224; 8/27/26 : 246; 9/21/26 : 268; 10/6/26 : 300

Source: Morgan Stanley Research Date Format : MM/DD/YY Price Target No Price Target Assigned (NA)
Stock Price (Not Covered by Current Analyst) Stock Price (Covered by Current Analyst)
Stock and Industry Ratings (abbreviations below) appear as ◆ Stock Rating/Industry View
Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) No Rating Available (NA)
Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

Effective January 13, 2014, the stocks covered by Morgan Stanley Asia Pacific will be rated relative to the analyst's industry (or industry team's) coverage.

Effective January 13, 2014, the industry view benchmarks for Morgan Stanley Asia Pacific are as follows: relevant MSCI country index or MSCI sub-regional index or MSCI AC Asia Pacific ex Japan Index.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Important disclosures regarding any material conflict of interest that can reasonably be expected to have influenced Morgan Stanley Smith Barney LLC's choice of a third-party research provider or the subject company of a third-party research report, are available on the Morgan Stanley Wealth Management disclosure website at www.morganstanley.com/online/researchdisclosures.
For Morgan Stanley specific disclosures, you may refer to https://www.morganstanley.com/eqr/disclosures/webapp/generalresearch.
Each Morgan Stanley research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

A member of Research who had or could have had access to the research prior to completion owns securities (or related derivatives) in the Analog Devices Inc., Broadcom Inc., Cisco Systems Inc, Microchip Technology Inc., NVIDIA Corp., Qualcomm Inc.. This person is not a research analyst or a member of research analyst's household.
Morgan Stanley Research policy is to update research reports as and when the Research Analyst and Research Management deem appropriate, based on developments with the issuer, the sector, or the market that may have a material impact on the research views or opinions stated therein. In addition, certain Research publications are intended to be updated on a regular periodic basis (weekly/monthly/quarterly/annual) and will ordinarily be updated with that frequency, unless the Research Analyst and Research Management determine that a different publication schedule is appropriate based on current conditions.
Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.
Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.
Morgan Stanley Research is provided to our clients through our proprietary research portal on Matrix and also distributed electronically by Morgan Stanley to clients. Certain, but not all, Morgan Stanley Research products are also made available to clients through third-party vendors or redistributed to clients through alternate electronic means as a convenience. For access to all available Morgan Stanley Research, please contact your sales representative or go to Matrix at http://www.morganstanley.com/matrix.
Any access and/or use of Morgan Stanley Research is subject to Morgan Stanley's Terms of Use (http://www.morganstanley.com/terms.html). By accessing and/or using Morgan Stanley Research, you are indicating that you have read and agree to be bound by our Terms of Use (http://www.morganstanley.com/terms.html). In addition you consent to Morgan Stanley processing your personal data and using cookies in accordance with our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html), including for the purposes of setting your preferences and to collect readership data so that we can deliver better and more personalized service and products to you. To find out more information about how Morgan Stanley processes personal data, how we use cookies and how to reject cookies see our Privacy Policy and our Global Cookies Policy (http://www.morganstanley.com/privacy_pledge.html). Please use the provided link to review the Terms and Conditions and Most Important Terms and Conditions for Morgan Stanley India Company Private Limited (https://www.morganstanley.com/assets/pdfs/about-us-global-offices/india/Terms_and_conditions.pdf) and the following link to review the audit report (https://ny.matrix.ms.com/eqr/research/webapp/researchdocs/MSICPL_Morgan_Stanley_Research_Audit_Report.pdf).
If you do not agree to our Terms of Use and/or if you do not wish to provide your consent to Morgan Stanley processing your personal data or using cookies please do not access our research.
Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the circumstances and objectives of those who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of an investment or strategy will depend on an investor's circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them. Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.
The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.
The "Important Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments or derivatives of securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.
With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.
Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.
Morgan Stanley may make investment decisions that are inconsistent with the recommendations or views in this report.
To our readers based in Taiwan or trading in Taiwan securities/instruments: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan Limited ("MSTL"). Such information is for your reference only. The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Any non-customer reader within the scope of Article 7-1 of the Taiwan Stock Exchange Recommendation Regulations accessing and/or receiving Morgan Stanley Research is not permitted to provide Morgan Stanley Research to any third party (including but not limited to related parties, affiliated companies and any other third parties) or engage in any activities regarding Morgan Stanley Research which may create or give the

appearance of creating a conflict of interest. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Neither this report nor any part of it is intended as, or shall constitute, provision of any consultancy or advisory service of securities investment as defined under PRC law. Such information is provided for your reference only.

Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A. located at Av. Brigadeiro Faria Lima, 3600, 6th floor, São Paulo - SP, Brazil; and is regulated by the Comissão de Valores Mobiliários; in Mexico by Morgan Stanley México, Casa de Bolsa, S.A. de C.V which is regulated by Comision Nacional Bancaria y de Valores. Paseo de los Tamarindos 90, Torre 1, Col. Bosques de las Lomas Floor 29, 05120 Mexico City; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents) and by Morgan Stanley Bank Asia Limited; in Singapore by Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research) and by Morgan Stanley Bank Asia Limited, Singapore Branch (Registration number T14FC0118J); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents; in Australia to "wholesale clients" and "retail clients" within the meaning of the Australian Corporations Act by Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents; in Korea by Morgan Stanley & Co International plc, Seoul Branch; in India by Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ("SEBI") and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com. Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts; in Germany and the European Economic Area where required by Morgan Stanley Europe S.E., authorised and regulated by Bundesanstalt fuer Finanzdienstleistungsaufsicht (BaFin) under the reference number 149169; in the US by Morgan Stanley & Co. LLC, which accepts responsibility for its contents. Morgan Stanley & Co. International plc, authorized by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority, disseminates in the UK research that it has prepared, and research which has been prepared by any of its affiliates, only to persons who (i) are investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the "Order"); (ii) are persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order; or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) may otherwise lawfully be communicated or caused to be communicated. RMB Morgan Stanley Proprietary Limited is a member of the JSE Limited and A2X (Pty) Ltd. RMB Morgan Stanley Proprietary Limited is a joint venture owned equally by Morgan Stanley International Holdings Inc. and RMB Investment Advisory (Proprietary) Limited, which is wholly owned by FirstRand Limited. Morgan Stanley Research is disseminated in Canada by Morgan Stanley Canada Limited and Morgan Stanley Wealth Management Canada Inc., members of the Canadian Investment Regulatory Organization (CIRO). The information in Morgan Stanley Research is being disseminated by Morgan Stanley Saudi Arabia, regulated by the Capital Market Authority in the Kingdom of Saudi Arabia, and is directed at Sophisticated investors only.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA) or by Morgan Stanley & Co. International plc (ADGM Branch), regulated by the Financial Services Regulatory Authority Abu Dhabi (the FSRA), and is directed at Professional Clients only, as defined by the DFSA or the FSRA, respectively. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria of a Professional Client. A distribution of the different MS Research ratings or recommendations, in percentage terms for Investments in each sector covered, is available upon request from your sales representative.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided exclusively to persons based on their risk and income preferences by the authorized firms. Comments and recommendations stated here are general in nature. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages relating to such data. The Global Industry Classification Standard (GICS) was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Indicators and trackers referenced in Morgan Stanley Research may not be used as, or treated as, a benchmark under Regulation EU 2016/1011, or any other similar framework.

The issuers and/or fixed income products recommended or discussed in certain fixed income research reports may not be continuously followed. Accordingly, investors should regard those fixed income research reports as providing stand-alone analysis and should not expect continuing analysis or additional reports relating to such issuers and/or individual fixed income products.

Morgan Stanley may hold, from time to time, material financial and commercial interests regarding the company subject to the Research report.

Registration granted by SEBI and certification from the National Institute of Securities Markets (NISM) in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

References to any prediction market or event contract do not constitute an offer, solicitation, recommendation, or endorsement to participate in any such market or contract. Morgan Stanley Research may not be distributed or made available in any jurisdiction where such distribution would be unlawful or otherwise prohibited by applicable law.

INDUSTRY COVERAGE: Telecom & Networking Equipment

COMPANY (TICKER)	RATING (AS OF)	PRICE* (11/02/2026)
Meta A Marshall		
Arista Networks (ANET.N)	O (10/31/2023)	$164.14
Axon Enterprise Inc (AXON.O)	O (12/03/2024)	$425.43
Ciena Corporation (CIEN.N)	E (10/10/2025)	$284.34
Cisco Systems Inc (CSCO.O)	O (04/08/2024)	$101.61
Coherent Corp (COHR.N)	E (12/13/2023)	$199.95
Corning Inc (GLW.N)	E (06/13/2024)	$123.20
F5 Inc (FFIV.O)	E (04/12/2022)	$324.55
Keysight Technologies Inc (KEYS.N)	O (07/13/2026)	$298.94
Lumentum Holdings Inc (LITE.O)	E (05/12/2021)	$684.40
Motorola Solutions Inc (MSI.N)	O (12/17/2025)	$487.31
Zebra Technologies Corporation (ZBRA.O)	E (12/02/2024)	$361.13

Stock Ratings are subject to change. Please see latest research for each company.
* Historical prices are not split adjusted.

INDUSTRY COVERAGE: Semiconductors

COMPANY (TICKER)	RATING (AS OF)	PRICE* (11/02/2026)
Ella Tulchinsky		
Infleqtion, Inc. (INFQ.N)	E (10/15/2026)	$8.15
Xanadu Quantum Technologies Limited (XNDU.O)	E (10/15/2026)	$2.60
Joseph Moore		
Advanced Micro Devices (AMD.O)	E (06/09/2024)	$466.84
Aeva Technologies Inc (AEVA.O)	E (07/19/2021)	$8.60
Allegro Microsystems Inc (ALGM.O)	O (02/13/2026)	$32.15
Ambarella Inc (AMBA.O)	O (03/29/2016)	$61.67
Amkor Technology Inc (AMKR.O)	E (11/08/2023)	$36.96
Analog Devices Inc. (ADI.O)	O (11/16/2023)	$412.85
Astera Labs Inc (ALAB.O)	O (05/11/2025)	$229.67
Broadcom Inc. (AVGO.O)	O (06/09/2024)	$322.23
Cerebras Systems (CBRS.O)	O (06/08/2026)	$96.36
GlobalFoundries Inc (GFS.O)	E (10/28/2024)	$41.82
Intel Corporation (INTC.O)	E (02/22/2023)	$59.97
IonQ Inc (IONQ.N)	E (04/25/2023)	$28.17
Marvell Technology Group Ltd (MRVL.O)	E (09/14/2015)	$171.41
Microchip Technology Inc. (MCHP.O)	E (07/10/2024)	$76.11
Micron Technology Inc. (MU.O)	O (10/06/2025)	$833.59
Navitas Semiconductor Corp (NVTS.O)	U (04/06/2025)	$7.93
NVIDIA Corp. (NVDA.O)	O (03/16/2023)	$202.06
NXP Semiconductor NV (NXPI.O)	O (02/11/2025)	$257.24
ON Semiconductor Corp. (ON.O)	++	$70.11
Qualcomm Inc. (QCOM.O)	E (06/24/2026)	$162.08
Quantinuum (QNT.O)	O (10/15/2026)	$30.95
SanDisk Corporation. (SNDK.O)	O (03/03/2025)	$1,075.08
Semtech Corp. (SMTC.O)	E (04/06/2025)	$122.38
Silicon Laboratories Inc. (SLAB.O)	E (01/19/2021)	$222.10
SiTime Corporation (SITM.O)	O (09/16/2026)	$417.90
Skyworks Solutions Inc (SWKS.O)	E (11/28/2018)	$85.17
Texas Instruments (TXN.O)	U (04/13/2020)	$302.02
Wolfspeed, INC (WOLF.N)	NR (04/06/2025)	$20.85
Lee Simpson		
Arm Holdings plc (ARM.O)	E (04/07/2026)	$196.79
Cadence Design Systems Inc (CDNS.O)	O (02/14/2024)	$329.51

PDF Solutions Inc (PDFS.O)	O (09/08/2026)	$38.97
Synopsys Inc. (SNPS.O)	O (09/08/2026)	$466.08

Stock Ratings are subject to change. Please see latest research for each company.
* Historical prices are not split adjusted.

© 2026 Morgan Stanley